Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data - Wikidata - awgldk - TriplyDB

Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data

Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data

http://www.wikidata.org/entity/Q30521476

about

Recent advances in understanding Type 1 Diabetes Antigen-Specific Regulatory T Cells and Low Dose of IL-2 in Treatment of Type 1 Diabetes Immune-directed therapy for type 1 diabetes at the clinical level: the Immune Tolerance Network (ITN) experience Type 1 diabetes The Juvenile Diabetes Research Foundation Network for Pancreatic Organ Donors with Diabetes (nPOD) Program: goals, operational model and emerging findings Insulitis in human type 1 diabetes: a comparison between patients and animal models Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report Disease modifying therapies in type 1 diabetes: Where have we been, and where are we going?Type 1 diabetes: translating mechanistic observations into effective clinical outcomes A Practical Review of C-Peptide Testing in Diabetes α1-Antitrypsin therapy downregulates toll-like receptor-induced IL-1β responses in monocytes and myeloid dendritic cells and may improve islet function in recently diagnosed patients with type 1 diabetes.Recommendations for the definition of clinical responder in insulin preservation studies New insight on human type 1 diabetes biology: nPOD and nPOD-transplantation.Recent lessons learned from prevention and recent-onset type 1 diabetes immunotherapy trials.Blood and islet phenotypes indicate immunological heterogeneity in type 1 diabetes Age at diagnosis predicts deterioration in glycaemic control among children and adolescents with type 1 diabetes.Gene expression analysis of human islets in a subject at onset of type 1 diabetes.Addition of rapamycin to anti-CD3 antibody improves long-term glycaemia control in diabetic NOD mice.Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial.β cell death and dysfunction during type 1 diabetes development in at-risk individuals.Thinking bedside at the bench: the NOD mouse model of T1DM.Changes in beta cell function during the proximate post-diagnosis period in persons with type 1 diabetes Biphasic decline of β-cell function with age in euglycemic nonobese diabetic mice parallels diabetes onset Comparison of Metabolic Outcomes in Children Diagnosed with Type 1 Diabetes Through Research Screening (Diabetes Autoimmunity Study in the Young [DAISY]) Versus in the Community.Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients.Type 1 diabetes immunotherapy using polyclonal regulatory T cells Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial Insulitis and β-Cell Mass in the Natural History of Type 1 Diabetes.Heterogeneity in recent-onset type 1 diabetes - a clinical trial perspective Interleukin-1 antagonism moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset.Proinsulin and heat shock protein 90 as biomarkers of beta-cell stress in the early period after onset of type 1 diabetes.Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial.Strategies for clinical trials in type 1 diabetes Insulitis in the pathogenesis of type 1 diabetes Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial.Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.The compelling case for anti-CD3 in type 1 diabetes.Effectiveness of early intensive therapy on β-cell preservation in type 1 diabetes.Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial.Real-time support of pediatric diabetes self-care by a transport team.

P2860

Q26766139-8D2F9665-66B8-4B43-A826-A548F95A9B4C Q26770386-4CFCAC30-FBAE-45EF-BDA1-5295329360D9 Q26850621-37271855-864D-46F6-AA28-50576E5E8B4A Q27000491-9CBA1378-AB26-4C5A-8687-1828A343AC63 Q27009048-152D567F-1255-4E65-9DA1-F9F4F7928F9A Q27023712-0656922A-EB45-4F6B-B837-1696E6D8E6B8 Q27687598-35CDFF02-A05E-4DF0-8068-EE50FEACEC0A Q28081034-236943FB-FDF4-46C5-ADA8-7BDAA6E94D5E Q28287737-BD5BA7A2-5EA8-4B42-B366-127656BA6689 Q33732640-55D1E8C4-F3A4-4C11-9A5D-F52CADFA4F27 Q33999020-462239BE-4A86-4ADD-8017-8420B4C75EA3 Q34077400-58CB0EF6-76D5-4E2C-8282-582989049A46 Q34240416-91039C0B-5C5A-4B9E-9050-B166A6069B7C Q34318993-46DD6C35-387E-4DAA-941B-B742EEA8F9E6 Q34393377-279F9DEF-DB6C-420B-B63A-FBDA433EB59E Q34419143-63C1CD0D-29B4-4A0A-84A0-3FA58426F4CA Q34691672-B0A92A39-0215-46F3-BD73-BCC1351F2161 Q34796651-4378B1AF-E65B-4B72-B7AF-E45664242447 Q34813843-1ACD693E-B56E-4100-A491-391F507C445A Q35183950-812C5746-A49A-4D6A-AE4F-4A71EBDF587C Q35911875-8F04B25F-876A-408B-92D8-DA78A1CF0099 Q36001688-EC58AE5D-D56F-4C74-B77C-86CA65221220 Q36006024-3D8DBD1D-3AE4-4FDE-8BF8-A7D49F56F3B8 Q36014076-FB932330-FDC0-49D2-A7C6-B68536D5EEED Q36216535-50639DAE-F20F-49F7-BB3C-ED530602431A Q36509805-7925E784-A0F0-42C9-B059-79F4A2C37F8A Q36510973-C129C2A4-B3D6-43D6-885C-D4234D4FE1B8 Q36608775-2A3C75FD-2363-4E32-A7FB-954BB205FCC9 Q36749719-D6927D0E-1D53-44AB-893F-9367C33144A7 Q36788764-42DC5300-2F2D-4345-B007-627D845651A1 Q36820961-A120CEDA-E111-4CD7-9D50-9CF0A7E66012 Q36908165-1345369D-4663-4701-8F28-156B61E0F81B Q36995370-43FD971A-18A0-49DE-8198-B2BEF9D55B3A Q37103789-DDB273F5-00D0-40DB-AAA5-6F2F2FA84B38 Q37251132-0F5E05CE-3E79-415C-BF35-47383D062E24 Q37251153-36D4B1F0-43F1-4223-8029-1C7F20FC85F3 Q37251171-40E19932-FF4A-4F80-932E-A05DFDA24099 Q37331265-4451193C-85A2-4F51-8B11-B3A5D705D731 Q37642554-897A8A20-3B7F-4216-9783-AA047A3583E7 Q37670213-493BA665-F44A-4B9E-8D50-E42C8FFB440C

P2860

Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data

http://www.wikidata.org/entity/Q30521476

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Fall in C-peptide during first ...... Type 1 Diabetes TrialNet data

@ast

Fall in C-peptide during first ...... Type 1 Diabetes TrialNet data

@en

type

label

Fall in C-peptide during first ...... Type 1 Diabetes TrialNet data

@ast

Fall in C-peptide during first ...... Type 1 Diabetes TrialNet data

@en

prefLabel

Fall in C-peptide during first ...... Type 1 Diabetes TrialNet data

@ast

Fall in C-peptide during first ...... Type 1 Diabetes TrialNet data

@en

P1433

Q30521476-21FF150C-ECD3-4CCD-B08E-AAF0DBF163CB

P1476

Q30521476-E3620F75-ED8E-4695-841E-3986FBFFB891

P2093

Q30521476-3A5F933D-7A3F-4C67-B471-EEE87FB3F729

Q30521476-4583BB7B-8FCB-46C9-87FD-9333143B40A2

Q30521476-4B6EF2FF-0CF8-4ABE-AAA7-6541B54FF1DA

Q30521476-62005F96-2B23-46B9-B8D3-E2A6037C0F37

Q30521476-690A0B17-F5DB-4B39-98FC-CEBA3BD593E0

Q30521476-6A02FE05-C154-4FCE-B4D1-366468BA3AF7

Q30521476-6AB52ECD-54AF-433C-BF5E-31AEAFD04D0A

Q30521476-85912D3B-FDBD-4D8E-BFC5-BE36E5578473

Q30521476-8B501A24-1DF8-42E4-AE99-B166537979D1

Q30521476-CA84CF60-FEC5-425F-BC8D-6387B14945D3

P2860

Q30521476-1944C2B9-8B8A-4397-9519-C7592862510B

Q30521476-227D423A-CDDA-4234-8FF0-2638B8DF9F15

Q30521476-257DC195-D8BE-4EAC-8C6A-5D0B5CFB524C

Q30521476-2AB1FD48-A740-4D2F-8738-FD176D24CAC5

Q30521476-3FBC8502-581F-4FE3-A09D-07444BE31DF9

Q30521476-45E61DB6-AAE4-4393-8C74-AFF48C824CC4

Q30521476-4E47423E-3A05-44C4-94C2-A00908D8DE75

Q30521476-5348C260-20EB-4D86-9580-099FDB049F03

Q30521476-59C494B0-F3ED-4826-BDB6-349DC851B5AA

Q30521476-5DD425CF-B83B-4E47-BDD7-C31273FA2463

P304

Q30521476-157A4ECE-1E27-4DB4-AA33-F118C45F95F6

P31

Q30521476-E1705E00-D7AA-4896-9B8C-140115ED1BEC

P356

Q30521476-135B374A-58AA-497F-8800-30442AE724BA

P407

Q30521476-56723867-7F4C-4109-AB7C-2F74C094F725

P433

Q30521476-3BFFAAC0-F377-4383-8E80-714F5E003244

P478

Q30521476-F607098A-4BC6-4F35-BE5B-244128960B3B

P50

Q30521476-45DD1169-8BBE-4F64-8D42-0C41EE158A01

P577

Q30521476-03874C3E-1E13-4566-989D-4F5C93AC45CD

P5875

Q30521476-FC603B7D-4A12-4CBD-9581-610987FCCE48

P698

Q30521476-3F6F2A04-31CC-472F-BC96-B521FE1AD615

P921

Q30521476-7E87DA89-E6F9-470B-911D-67D9508D5D76

P932

Q30521476-757CB593-0FEA-411F-9C73-B81D57532CA1

P356

P1433

P1476

Fall in C-peptide during first ...... Type 1 Diabetes TrialNet data

@en

P2093

Carla J Greenbaum

http://www.w3.org/2001/XMLSchema#string

Craig A Beam

http://www.w3.org/2001/XMLSchema#string

David Boulware

http://www.w3.org/2001/XMLSchema#string

Heidi Krause-Steinrauf

http://www.w3.org/2001/XMLSchema#string

Jay M Sosenko

http://www.w3.org/2001/XMLSchema#string

Jay S Skyler

http://www.w3.org/2001/XMLSchema#string

Jerry P Palmer

http://www.w3.org/2001/XMLSchema#string

Kevan C Herold

http://www.w3.org/2001/XMLSchema#string

Mark D Pescovitz

http://www.w3.org/2001/XMLSchema#string

Paula McGee

http://www.w3.org/2001/XMLSchema#string

P2860

First-phase insulin release during the intravenous glucose tolerance test as a risk factor for type 1 diabetes.

Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetes

Residual insulin production and pancreatic ß-cell turnover after 50 years of diabetes: Joslin Medalist Study.

A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes.

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

Metabolic tests to determine risk for type 1 diabetes in clinical trials.

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial.

Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.

The rising incidence of type 1 diabetes is accounted for by cases with lower-risk human leukocyte antigen genotypes

Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes

P304

2066-2073

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DB11-1538

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

61

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-06-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225296227

http://www.w3.org/2001/XMLSchema#string

P698

22688329

http://www.w3.org/2001/XMLSchema#string

P921

type-1 diabetes

P932

3402330

http://www.w3.org/2001/XMLSchema#string